| pubmed-article:10997967 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10997967 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10997967 | lifeskim:mentions | umls-concept:C0040028 | lld:lifeskim |
| pubmed-article:10997967 | lifeskim:mentions | umls-concept:C0085183 | lld:lifeskim |
| pubmed-article:10997967 | lifeskim:mentions | umls-concept:C0006463 | lld:lifeskim |
| pubmed-article:10997967 | lifeskim:mentions | umls-concept:C0020402 | lld:lifeskim |
| pubmed-article:10997967 | lifeskim:mentions | umls-concept:C0206034 | lld:lifeskim |
| pubmed-article:10997967 | lifeskim:mentions | umls-concept:C1517942 | lld:lifeskim |
| pubmed-article:10997967 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:10997967 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:10997967 | pubmed:dateCreated | 2000-10-10 | lld:pubmed |
| pubmed-article:10997967 | pubmed:abstractText | We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis. However, the relatively short follow-up (median 27 months) did not enable the evaluation of the risk of developing secondary malignancies. In this study, we report the long-term outcome of the 114 patients included in the trial: 56 patients randomized to receive HU and 58 patients to receive no cytoreductive therapy. Before randomization, 15 patients had been treated with busulphan. During the observation period, 29 patients (50%) shifted from the control to the HU group mainly because of thrombosis. Median follow-up was 73 months (range 3-94). Analysis was by intention to treat and, when indicated, by treatment. When analysed by intention to treat, 46 out of 54 patients (85%) originally randomized in the HU group are alive, compared with 49 of 58 patients (84%) in the control group [not significant (n.s.)]. Five patients (9%) in the HU group and 26 patients (45%) in the control group had thrombosis (P < 0.0001). Seven patients (13%) in the HU group developed secondary acute leukaemia, myelodysplastic syndromes or solid tumours, compared with only one of the control group patients (1.7%) (P = 0.032). The occurrence of secondary malignancies was also analysed by treatment: none of the 20 patients who had never been treated with chemotherapy developed neoplasia vs. three of the 77 patients given HU only (3.9% n.s.) and five of the 15 patients given busulphan plus HU (33% P < 0. 0001). This study showed that: (a) HU reduced the risk of thrombosis in ET patients; (b) the sequential use of busulphan and HU significantly increased the risk of second malignancies; and (c) overall survival was not affected by HU therapy. | lld:pubmed |
| pubmed-article:10997967 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10997967 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10997967 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10997967 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10997967 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10997967 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10997967 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10997967 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:10997967 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:10997967 | pubmed:author | pubmed-author:BarbuiTT | lld:pubmed |
| pubmed-article:10997967 | pubmed:author | pubmed-author:RodeghieroFF | lld:pubmed |
| pubmed-article:10997967 | pubmed:author | pubmed-author:RuggeriMM | lld:pubmed |
| pubmed-article:10997967 | pubmed:author | pubmed-author:FinazziGG | lld:pubmed |
| pubmed-article:10997967 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10997967 | pubmed:volume | 110 | lld:pubmed |
| pubmed-article:10997967 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10997967 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10997967 | pubmed:pagination | 577-83 | lld:pubmed |
| pubmed-article:10997967 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:meshHeading | pubmed-meshheading:10997967... | lld:pubmed |
| pubmed-article:10997967 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10997967 | pubmed:articleTitle | Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. | lld:pubmed |
| pubmed-article:10997967 | pubmed:affiliation | Divisions of Haematology, Ospedali Riuniti, Bergamo, and Ospedale S. Bortolo, Vicenza, Italy. | lld:pubmed |
| pubmed-article:10997967 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10997967 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10997967 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10997967 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10997967 | lld:pubmed |
